Robinson T E, Becker J B
Brain Res. 1986 Jun;396(2):157-98. doi: 10.1016/s0006-8993(86)80193-7.
Some people who repeatedly use stimulant drugs, such as amphetamine (AMPH), develop an AMPH-induced psychosis that is similar to paranoid schizophrenia. There has been, therefore, considerable interest in characterizing the effects of chronic stimulant drug treatment on brain and behavior in non-human animals, and in developing an animal model of AMPH psychosis. A review of this literature shows that in non-human animals chronic AMPH treatment can produce at least two different syndromes, and both of these have been proposed as animal models of AMPH psychosis. The first syndrome is called 'AMPH neurotoxicity', and is produced by maintaining elevated brain concentrations of AMPH for prolonged periods of time. AMPH neurotoxicity is characterized by what has been termed 'hallucinatory-like' behavior, which occurs in association with brain damage resulting in the depletion of striatal DA and other brain monoamines. The second syndrome is called 'behavioral sensitization', and is produced by the repeated intermittent administration of lower doses of AMPH. Behavioral sensitization is characterized by a progressive and enduring enhancement in many AMPH-induced behaviors, and is not accompanied by brain damage or monoamine depletion. It is argued that the changes in the brain and behavior associated with the phenomenon of behavioral sensitization provide a better 'model' of AMPH psychosis than those associated with AMPH neurotoxicity. Much of the review involves a critical analysis of hypotheses regarding the biological basis of behavioral sensitization. Research on this question has focused on mesotelencephalic DA systems, and suggestions that behavioral sensitization is accompanied by: an increase in postsynaptic DA receptors; an increase in DA synthesis; an increase in DA utilization and/or release; and a decrease in DA autoreceptors, are evaluated. It is concluded that there is not convincing evidence for an increase in postsynaptic DA receptors or in DA synthesis in animals sensitized to AMPH. In contrast, there is strong evidence to support the notion that behavioral sensitization is due to enhanced mesotelencephalic DA release, especially upon re-exposure to the drug. The evidence that this enhancement in DA release is due to autoreceptor subsensitivity was found to be equivocal, and therefore other hypotheses should be entertained. Lastly, evidence is discussed in support of the idea that behavioral sensitization is not unique to the psychopharmacology of stimulant drugs, but may be produced by many environmental stimuli that directly or indirectly activate brain catecholamine systems.(ABSTRACT TRUNCATED AT 400 WORDS)
一些反复使用兴奋剂药物(如苯丙胺)的人会患上与偏执型精神分裂症相似的苯丙胺诱发精神病。因此,人们对描述慢性兴奋剂药物治疗对非人类动物大脑和行为的影响,以及建立苯丙胺精神病的动物模型产生了浓厚兴趣。对该文献的综述表明,在非人类动物中,慢性苯丙胺治疗可产生至少两种不同的综合征,且这两种综合征都被提议作为苯丙胺精神病的动物模型。第一种综合征称为“苯丙胺神经毒性”,是通过长时间维持大脑中升高的苯丙胺浓度产生的。苯丙胺神经毒性的特征是出现所谓的“类幻觉”行为,这种行为与导致纹状体多巴胺(DA)和其他脑单胺耗竭的脑损伤有关。第二种综合征称为“行为敏化”,是通过反复间歇性给予较低剂量的苯丙胺产生的。行为敏化的特征是许多苯丙胺诱发行为的逐渐和持久增强,且不伴有脑损伤或单胺耗竭。有人认为,与行为敏化现象相关的大脑和行为变化比与苯丙胺神经毒性相关的变化更能提供苯丙胺精神病的“模型”。综述的大部分内容涉及对关于行为敏化生物学基础的假设的批判性分析。对这个问题的研究集中在中脑边缘多巴胺系统,有人提出行为敏化伴随着:突触后多巴胺受体增加;多巴胺合成增加;多巴胺利用和/或释放增加;以及多巴胺自身受体减少,并对这些观点进行了评估。结论是,对于对苯丙胺敏感的动物,没有令人信服的证据表明突触后多巴胺受体或多巴胺合成增加。相反,有强有力的证据支持行为敏化是由于中脑边缘多巴胺释放增强,尤其是再次接触该药物时。多巴胺释放增强是由于自身受体敏感性降低的证据被发现模棱两可,因此应该考虑其他假设。最后,讨论了支持行为敏化并非兴奋剂药物精神药理学所特有的观点的证据,而是可能由许多直接或间接激活脑儿茶酚胺系统的环境刺激产生。(摘要截短至400字)